EXPEDITED REVIEW
Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery
The NAPA Trial
Robert M. Mentzer, Jr, MD, FACC*,*,
Mehmet C. Oz, MD, FACC ,
Robert N. Sladen, MD, FCCM ,
Allen H. Graeve, MD, FACS ,
Robert F. Hebeler, Jr, MD||,
John M. Luber, Jr, MD, FACS¶,
Nicholas G. Smedira, MD, FACC# on behalf of the NAPA Investigators
* Division of Cardiothoracic Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan
Division of Cardiothoracic Surgery, College of Physicians & Surgeons, Columbia University, New York, New York
Department of Anesthesiology, College of Physicians & Surgeons, Columbia University, New York, New York
MultiCare Cardiothoracic Surgical Associates, Tacoma General Hospital, Tacoma, Washington
|| Department of Surgery, Baylor University Medical Center, Dallas, Texas
¶ Franciscan Health System Research Center, Tacoma, Washington
# Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic, Cleveland, Ohio
Manuscript received August 1, 2006;
revised manuscript received September 26, 2006,
accepted October 12, 2006.
* Reprint requests and correspondence: Dr. Robert M. Mentzer, Jr., Wayne State University School of Medicine, Department of Surgery, Division of Cardiothoracic Surgery, 1241 Scott Hall, 540 E. Canfield, Detroit, Michigan 48201. (Email: rmentzer{at}med.wayne.edu).
OBJECTIVES: The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).
BACKGROUND: Given the hemodynamic, neurohormonal, and renal effects of natriuretic peptides, nesiritide might be useful in the management of patients undergoing cardiac surgery.
METHODS: This prospective, double-blind, exploratory evaluation randomly assigned patients with ejection fraction  40% who were undergoing CABG with anticipated use of CPB to receive either nesiritide or placebo, in addition to usual care, for 24 to 96 h after induction of anesthesia. Postoperative renal function, hemodynamics, and drug use (primary end points) were assessed in patients who underwent CABG using CPB; mortality and safety (secondary end points) were assessed in all patients who received the study drug.
RESULTS: Of 303 randomized patients, 279 received the study drug and 272 underwent CABG using CPB. Compared with placebo, nesiritide was associated with a significantly attenuated peak increase in serum creatinine (0.15 ± 0.29 mg/dl vs. 0.34 ± 0.48 mg/dl; p < 0.001) and a smaller fall in glomerular filtration rate (–10.8 ± 19.3 ml/min/1.73 m2 vs. –17.2 ± 21.9 ml/min/1.73 m2; p = 0.001) during hospital stay or by study day 14, and a greater urine output (2,926 ± 1,179 ml vs. 2,350 ± 1,066 ml; p < 0.001) during the initial 24 h after surgery. In addition, nesiritide-treated patients had a shorter hospital stay (p = 0.043) and lower 180-day mortality (p = 0.046).
CONCLUSIONS: Nesiritide in the setting of CABG with CPB is associated with improved postoperative renal function and possibly enhanced survival. (The NAPA Trial; http://www.clinicaltrials.gov/ct/show; NCT00090792
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | CABG = coronary artery bypass grafting | | CI = confidence interval | | CPB = cardiopulmonary bypass | | GFR = glomerular filtration rate | | HR = hazard ratio | | ICU = intensive care unit | | LOS = length of stay | | LV = left ventricular | | SCr = serum creatinine |
|
Related Article
-
Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery
- Israel Belenkie
J. Am. Coll. Cardiol. 2007 49: 727-728.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
U. Elkayam, M. W. Akhter, M. Liu, P. Hatamizadeh, and M. N. Barakat
Assessment of Renal Hemodynamic Effects of Nesiritide in Patients With Heart Failure Using Intravascular Doppler and Quantitative Angiography
J. Am. Coll. Cardiol. Img.,
November 1, 2008;
1(6):
765 - 771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. McKown Dyke, D. Bhatia, S. Aronson, N. Moazami, and R. M. Mentzer Jr.
Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction.
J. Thorac. Cardiovasc. Surg.,
November 1, 2008;
136(5):
1369 - 1370.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cataliotti, H. H. Chen, J. A. Schirger, F. L. Martin, G. Boerrigter, L. C. Costello-Boerrigter, K. D. James, K. Polowy, M. A. Miller, N. B. Malkar, et al.
Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension
Circulation,
October 21, 2008;
118(17):
1729 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cote and A. Denault
Transesophageal echocardiography-related complications: [Complications associees a l'echocardiographie transoesophagienne]
Can J Anesth,
September 1, 2008;
55(9):
622 - 647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ryan, D. A. Rosen, and J. D. Tobias
Preliminary Experience With Nesiritide in Pediatric Patients Less Than 12 Months of Age
J Intensive Care Med,
September 1, 2008;
23(5):
321 - 328.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. S. Stewart, M. J. Russo, T. P. Martens, T. M. Naseem, M. C. Deng, R. Wang, M. Argenziano, M. Oz, and Y. Naka
Longer duration of continuous-flow ventricular assist device support predicts greater hemodynamic compromise after return of pulsatility.
J. Thorac. Cardiovasc. Surg.,
August 1, 2008;
136(2):
524 - 525.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown, R. P. Cochran, T. A. MacKenzie, A. P. Furnary, K. S. Kunzelman, C. S. Ross, C. W. Langner, D. C. Charlesworth, B. J. Leavitt, L. J. Dacey, et al.
Long-term survival after cardiac surgery is predicted by estimated glomerular filtration rate.
Ann. Thorac. Surg.,
July 1, 2008;
86(1):
4 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Lisy, B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett Jr
Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP.
J. Am. Coll. Cardiol.,
July 1, 2008;
52(1):
60 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Beaver, A. Bihorac, and A. A. Ejaz
Reply to the Editor:
J. Thorac. Cardiovasc. Surg.,
July 1, 2008;
136(1):
233 - 233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Burnett Jr and J. Korinek
The Tumultuous Journey of Nesiritide: Past, Present, and Future
Circ Heart Fail,
May 1, 2008;
1(1):
6 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Yancy, H. Krum, B. M. Massie, M. A. Silver, L. W. Stevenson, M. Cheng, S. S. Kim, R. Evans, and for the FUSION II Investigators
Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial
Circ Heart Fail,
May 1, 2008;
1(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Herget-Rosenthal, F. Saner, and L. S. Chawla
Approach to Hemodynamic Shock and Vasopressors
Clin. J. Am. Soc. Nephrol.,
March 1, 2008;
3(2):
546 - 553.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kazory and E. A. Ross
Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Circulation,
February 19, 2008;
117(7):
975 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Silver and C. W. Yancy
Using Homeostatic Peptides in Decompensated Heart Failure: A Reasonable Paradigm But a Flawed Practice?
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1841 - 1843.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler
Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1835 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr.
Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2007;
293(4):
R1580 - R1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Chen, T. M. Sundt, D. J. Cook, D. M. Heublein, and J. C Burnett Jr
Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study
Circulation,
September 11, 2007;
116(11_suppl):
I-134 - I-138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dunn and S. Sachak
Nesiritide and renal function after cardiac surgery
Am. J. Health Syst. Pharm.,
August 1, 2007;
64(15):
1582 - 1584.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Belenkie
Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
727 - 728.
[Full Text]
[PDF]
|
|
|
|
